Literature DB >> 1639266

Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene.

M Koizumi1, H Kamiya, E Ohtsuka.   

Abstract

We have designed hammerhead ribozymes that cleave c-Ha-ras mRNA mutated at codon 12 (GGU----GUU). Plasmids containing the ribozyme-encoding genes were expressed under the control of the long terminal repeats of Rous sarcoma virus in NIH3T3 cells transfected with the activated c-Ha-ras gene. These ribozymes were found to inhibit formation of foci (by about 50%) by cleaving the oncogene mRNA, rather than by hybridizing to it. Furthermore, when the activated c-Ha-ras gene was cotransfected with the ribozyme-encoding gene, three morphologically flat colonies were found and isolated. We also found that expression of c-Ha-ras was suppressed in cells containing ribozymes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639266     DOI: 10.1016/0378-1119(92)90727-7

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  13 in total

Review 1.  Therapeutic genes for cancer gene therapy.

Authors:  W Walther; U Stein
Journal:  Mol Biotechnol       Date:  1999-11       Impact factor: 2.695

Review 2.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

3.  A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.

Authors:  M Y Chang; S J Won; H S Liu
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 4.  Targeting signal transduction for disease therapy.

Authors:  A Levitzki
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.064

Review 5.  Ribozymes. Their functions and strategies for their use.

Authors:  S A Gibson; E J Shillitoe
Journal:  Mol Biotechnol       Date:  1997-04       Impact factor: 2.695

Review 6.  Inhibition of gene expression with ribozymes.

Authors:  P Marschall; J B Thomson; F Eckstein
Journal:  Cell Mol Neurobiol       Date:  1994-10       Impact factor: 5.046

7.  Interventional genetics and cancer treatment.

Authors:  N R Lemoine; K Sikora
Journal:  BMJ       Date:  1993-03-13

8.  Ribozyme-mediated reversal of the multidrug-resistant phenotype.

Authors:  K J Scanlon; H Ishida; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

Review 9.  Antisense oncogene and tumor suppressor gene therapy of cancer.

Authors:  W W Zhang
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

10.  An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious virus yield.

Authors:  Z Xing; J L Whitton
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.